Program
baxdrostat
Also written as “Baxdrostat”, “CIN-107” and “Baxdrostat/dapagliflozin”.
Its studies are mostly in Hypertension · Renal Insufficiency, Chronic · Hyperaldosteronism · Heart Failure · Atherosclerosis, led by 2 companies.
Drug pageBaxdrostat: every studyAll 28 studies of it, academic ones too, with its approvals, label and forms.Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| AstraZeneca | 256 open or running | phase 3since Sep 6, 2023 | Aug 17, 2020 | Dec 10, 2026phase 2 · NCT07222917 |
| Hoffmann-La Rocheits history only | 10 open or running | phase 1since Nov 20, 2013 | Nov 20, 2013 | none ahead |
Also a collaborator on its studies: Tigermed Consulting and Parexel.
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and studies of AstraZeneca only; the figures above count every company.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). An open circle marks the day WHO proposed its name. Dates ahead are the sponsors’ estimates.
Not listed one by one: 8 earlier studies, Aug 17, 2020 to Aug 12, 2022.
- Jul 28, 2021Named baxdrostatINNProposed as its International Nonproprietary Name in WHO's List 125 · before, CIN-107, RO6836191
- Jul 3, 20234 phase 1 studies in HypertensionNCT05963009, NCT05961397, NCT05961384 and 1 more
- Sep 6, 2023Phase 3 study in HypertensionNCT06034743 · 796 enrolled · United States, Argentina, Australia and more
- Dec 5, 2023Phase 3 study in HypertensionNCT06168409 · 218 enrolled · United States, Argentina, Australia and more
- Dec 21, 2023Phase 1 study in Healthy ParticipantsNCT06194032 · 28 enrolled · Germany
- Feb 13, 2024Phase 3 study in Renal Insufficiency, ChronicNCT06268873 · 2,554 enrolled · United States, Argentina, Australia and more
- Mar 22, 2024Phase 2 study in Uncontrolled HypertensionNCT06336356 · 48 enrolled · United States
- Mar 27, 2024Phase 3 study in HypertensionNCT06344104 · 326 enrolled · Argentina, Australia, China and more
- Apr 5, 2024Phase 1 study in Healthy ParticipantsNCT06357520 · 14 enrolled · United States
- Oct 23, 2024Phase 1 study in Healthy ParticipantsNCT06657105 · 22 enrolled · United States
- Nov 5, 2024Phase 3 study in Heart FailureNCT06677060 · 11,300 planned · United States, Argentina, Australia and more
- Dec 16, 2024Phase 3 study in Renal Insufficiency, ChronicNCT06742723 · 5,000 planned · United States, Argentina, Australia and more
- May 16, 2025Phase 3 study in HyperaldosteronismNCT07007793 · 212 enrolled · United States, Australia, Canada and more
- Oct 17, 2025Phase 2 study in Renal Insufficiency, ChronicNCT07222917 · 222 enrolled · United States, Argentina, Bulgaria and more
- May 22, 2026Phase 3 study in Uncontrolled HypertensionNCT07686120 · 286 planned · China
Ahead
- Dec 10, 2026Primary completion: phase 2 study in Renal Insufficiency, ChronicNCT07222917
- Jul 27, 2027Primary completion: phase 3 study in HyperaldosteronismNCT07007793
- Feb 9, 2028Primary completion: phase 3 study in Uncontrolled HypertensionNCT07686120
- Feb 24, 2028Primary completion: phase 3 study in Renal Insufficiency, ChronicNCT06268873
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
All 25 AstraZeneca leads, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07686120Uncontrolled Hypertension · China | 3 | Recruiting | Feb 9, 2028 | 286 |
| NCT07222917Renal Insufficiency, Chronic · United States, Argentina, Bulgaria and more | 2 | Active, not recruiting | Dec 10, 2026 | 222 |
| NCT07007793Hyperaldosteronism · United States, Australia, Canada and more | 3 | Active, not recruiting | Jul 27, 2027 | 212 |
| NCT06742723Renal Insufficiency, Chronic · United States, Argentina, Australia and more | 3 | Recruiting | Dec 18, 2029 | 5,000 |
| NCT06677060Heart Failure · United States, Argentina, Australia and more | 3 | Recruiting | Dec 17, 2029 | 11,300 |
| NCT06657105Healthy Participants · United States | 1 | Completed | Feb 3, 2025 | 22 |
| NCT06357520Healthy Participants · United States | 1 | Completed | Jun 17, 2024 | 14 |
| NCT06344104Hypertension · Argentina, Australia, China and more | 3 | Completed | Nov 24, 2025 | 326 |
| NCT06336356Uncontrolled Hypertension · United States | 2 | Completed | Dec 4, 2024 | 48 |
| NCT06268873Renal Insufficiency, Chronic · United States, Argentina, Australia and more | 3 | Active, not recruiting | Feb 24, 2028 | 2,554 |
| NCT06194032Healthy Participants · Germany | 1 | Completed | May 13, 2024 | 28 |
| NCT06168409Hypertension · United States, Argentina, Australia and more | 3 | Completed | Aug 17, 2025 | 218 |
| NCT06034743Hypertension · United States, Argentina, Australia and more | 3 | Completed | May 21, 2025 | 796 |
| NCT05966324Hypertension · United States | 1 | Completed | Sep 20, 2022 | 41 |
| NCT05963009Hypertension · United States | 1 | Completed | Apr 29, 2020 | 14 |
| NCT05961397Hypertension · United States | 1 | Completed | Apr 15, 2022 | 20 |
| NCT05961384Hypertension · United States | 1 | Completed | Jan 15, 2022 | 8 |
| NCT05526690Hypertension · United States | 1 | Completed | Dec 12, 2020 | 27 |
| NCT05500820Hypertension · United States | 1 | Completed | Apr 3, 2020 | 56 |
| NCT05470725Hypertension · United States | 1 | Completed | Apr 30, 2021 | 33 |
| NCT05432167Renal Insufficiency, Chronic · United States | 2 | Completed | May 2, 2024 | 195 |
| NCT05459688Hypertension · United States | 2 | Completed | Nov 7, 2023 | 175 |
| NCT05137002Uncontrolled Hypertension · United States | 2 | Completed | Sep 13, 2022 | 249 |
| NCT04605549Hyperaldosteronism · United States | 2 | Completed | Oct 28, 2024 | 15 |
| NCT04519658Resistant Hypertension · United States | 2 | Completed | Jun 14, 2022 | 275 |
How it is read
Names in the registry
- “Baxdrostat”, 8 entries
- “CIN-107”, 7 entries
- “Baxdrostat/dapagliflozin”, 3 entries
- “baxdrostat”, 3 entries
- “RO6836191”, 3 entries
Conditions, from the studies’ own filings
- Hypertension, 15 studies
- Renal Insufficiency, Chronic, 4 studies
- Hyperaldosteronism, 2 studies
- Heart Failure, 1 study
- Atherosclerosis, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.